A recent study published in the Journal of Cachexia, Sarcopenia and Muscle investigates the interaction between rapamycin and exercise in older adults, revealing that rapamycin may blunt the benefits of physical activity. Conducted by an international team, the trial involved 40 sedentary participants aged 65-85 who underwent a 13-week exercise program while receiving either 6 mg of rapamycin or a placebo weekly. Although most results did not achieve statistical significance, trends indicated that those on rapamycin experienced reduced functional gains compared to the placebo group.

The findings underscore a potential conflict between rapamycin’s mechanism of action and the anabolic demands of exercise. Rapamycin inhibits mTORC1, a critical regulator of muscle protein synthesis, shifting the body into a maintenance mode that enhances autophagy but may hinder muscle growth and endurance. The study’s primary endpoint—improvement in chair-stand performance—favored the placebo group, suggesting that rapamycin’s effects may interfere with the expected anabolic response to exercise. This aligns with previous rodent studies indicating that sustained mTORC1 inhibition can suppress muscle adaptation.

The implications of this research are significant for the field of geroprotective interventions. It challenges the notion of combining rapamycin and exercise for synergistic benefits, suggesting that the timing and dosing of rapamycin require careful consideration. While the “cycling hypothesis” was proposed to mitigate these effects, the current findings indicate that weekly dosing may not be compatible with exercise-induced adaptations. This raises important questions about the long-term use of rapamycin in aging populations and highlights the necessity for further research to explore optimal dosing strategies that could potentially harmonize the benefits of both interventions.

Source: lifespan.io